Interdisciplinary Metabolic Medicine Trials Unit, Department of Endocrinology and Diabetology, Medical University of Graz, 8036 Graz, Austria.
Intensive Care Unit, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
Viruses. 2022 Apr 8;14(4):777. doi: 10.3390/v14040777.
This study evaluated and compared the performance of simplified acute physiology score 3 (SAPS 3) for predicting in-hospital mortality in COVID-19 patients admitted to intensive care units (ICUs) with and without diabetes in Austria. The Austrian national public health institute (GÖG) data of COVID-19 patients admitted to ICUs (n = 5850) were analyzed. Three versions of SAPS 3 were used: standard equation, Central European equation, and Austrian equation customized for COVID-19 patients. The observed in-hospital mortality was 38.9%, 42.9%, and 37.3% in all, diabetes, and non-diabetes patients, respectively. The overall C-statistics was 0.69 with an insignificant (p = 0.193) difference between diabetes (0.70) and non-diabetes (0.68) patients. The Brier score was > 0.20 for all SAPS 3 equations in all cohorts. Calibration was unsatisfactory for both standard and Central European equations in all cohorts, whereas it was satisfactory for the Austrian equation in diabetes patients only. The SAPS 3 score demonstrated low discrimination and accuracy in Austrian COVID-19 patients, with an insignificant difference between diabetes and non-diabetes. All equations were miscalibrated particularly in non-diabetes patients, while the Austrian equation showed satisfactory calibration in diabetes patients only. Both uncalibrated and calibrated versions of SAPS 3 should be used with caution in COVID-19 patients.
本研究评估和比较了简化急性生理学评分 3 版(SAPS 3)在预测奥地利重症监护病房(ICU)内合并和不合并糖尿病的 COVID-19 患者住院死亡率方面的性能。分析了奥地利国家公共卫生研究所(GÖG)收治 ICU 的 COVID-19 患者(n=5850)的数据。使用了 SAPS 3 的三个版本:标准方程、中欧方程和针对 COVID-19 患者定制的奥地利方程。所有、糖尿病和非糖尿病患者的观察住院死亡率分别为 38.9%、42.9%和 37.3%。总体 C 统计量为 0.69,糖尿病(0.70)和非糖尿病(0.68)患者之间无显著差异(p=0.193)。所有 SAPS 3 方程在所有队列中的 Brier 评分均>0.20。在所有队列中,标准和中欧方程的校准均不理想,而仅在糖尿病患者中,奥地利方程的校准是令人满意的。SAPS 3 评分在奥地利 COVID-19 患者中表现出较低的区分度和准确性,糖尿病和非糖尿病患者之间无显著差异。所有方程在非糖尿病患者中均存在较大的偏差,而奥地利方程仅在糖尿病患者中显示出令人满意的校准。SAPS 3 的未经校准和校准版本在 COVID-19 患者中均应谨慎使用。